Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.70 |
| ▸ | SNCA | P37840 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | TOP1 | P11387 | 1/20 | 0.56 |
| ▸ | TOP2A | P11388 | 1/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16677959 | 0.86 | NQO2 (0.84) | NQO2SNCANPC1RAB9ATOP1 | |
| SCHEMBL5375629 | 0.84 | NPC1 (0.72) | NQO2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL677476 | 0.84 | MEN1 (0.67) | SNCANPC1RAB9ATOP1TOP2A | |
| SCHEMBL2415708 | 0.83 | PTPN1 (0.76) | NQO2SNCANPC1RAB9AMEN1 | |
| SCHEMBL4491689 | 0.83 | PTPN1 (0.76) | NQO2SNCANPC1RAB9AMEN1 | |
| SCHEMBL715515 | 0.82 | NQO2 (1.00) | NQO2SNCANPC1RAB9ATOP1 | |
| SCHEMBL2915371 | 0.80 | MEN1 (0.81) | SNCANPC1RAB9ATOP1TOP2A | |
| SCHEMBL900928 | 0.80 | DEGS1 (0.75) | NQO2SNCANPC1RAB9ATOP1 | |
| SCHEMBL899585 | 0.80 | DEGS1 (0.75) | NQO2SNCANPC1RAB9ATOP1 | |
| SCHEMBL8420639 | 0.80 | DEGS1 (0.75) | NQO2SNCANPC1RAB9ATOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055007-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | Lifex Biolabs, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20210139435-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | Lifex Biolabs, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139435-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | PTGDR, NR3C1, PTGIR | NQO2 967/4885SNCA 384/4885NPC1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.